# Haploidentical PBMC Transplant for Severe Congenital Anemias

> **NCT00977691** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **National Heart, Lung, and Blood Institute (NHLBI)** · enrollment: 23 (actual)

## Conditions studied

- Sickle Cell Anemia

## Interventions

- **PROCEDURE:** PBSC Transplant
- **DRUG:** Alemtuzumab
- **DRUG:** Sirolimus
- **DRUG:** Cyclophosphamide
- **PROCEDURE:** Low Dose Irradiation

## Key facts

- **NCT ID:** NCT00977691
- **Lead sponsor:** National Heart, Lung, and Blood Institute (NHLBI)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2009-12-14
- **Primary completion:** 2018-08-01
- **Final completion:** 2026-09-10
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2026-04-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00977691

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00977691, "Haploidentical PBMC Transplant for Severe Congenital Anemias". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00977691. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*